Clinical Trial: A Phase I/II Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847905) titled 'A Phase I/II Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors' on Sept. 23.

Brief Summary: For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors.

For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.

Study Start Date: Oct. 19

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor Cancer

Inter...